Appendix C. Clinical Trial Efficacy Data for Daily, Oral Tenofovir Disoproxil Fumarate/Emtricitabine as Pre-Exposure Prophylaxis

Body
Studya Population Regimen Efficacy
(95% CI)
Percentage of Participants with Detectable Plasma Levels of TFV
Partners PrEP
(n = 4,758)1
Serodiscordant couples in Kenya and Uganda

n = 1,579 randomized to receive TDF/FTC
TDF/FTC 75% (55% to 87%) 82%b
CDC TDF2
(n = 1,215)2
Heterosexual men and women in Botswana TDF/FTC 63% (22% to 83%) 79%
Fem-PrEP
(n = 2,056)3
Heterosexual women in South Africa, Kenya, and Tanzania TDF/FTC No effect 24%
VOICE
(n = 5,029)4
Heterosexual women in South Africa, Uganda, and Zimbabwe n = 1,003 randomized to receive TDF/FTC TDF/FTC No effect 29%
a The data in this table are from studies that included heterosexual women.
b Among the patients who achieved detectable plasma levels of TFV, the efficacy estimate for daily TDF/FTC was 91% (95% CI, 47% to 98%).4

Key: CI = confidence interval; FTC = emtricitabine; PrEP = pre=exposure prophylaxis TDF = tenofovir disoproxil fumarate; TFV = tenofovir